# Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

> **NCT03900884** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 17 (actual)

## Conditions studied

- Breast Neoplasm Female

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Palbociclib
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT03900884
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-25
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03900884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03900884, "Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT03900884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*